Exscientia, GlaxoSmithKline ink £33 million AI-driven drug discovery partnership

615

Exscientia, a company that uses artificial intelligence and machine learning for drug discovery,  has entered into a collaboration with GlaxoSmithKline (GSK).

The company will receive research payments from GSK to undertake new discovery programs with nominated targets with the goal of delivering pre-clinical candidates. In addition to research funding, Exscientia is also eligible to receive near-term lead and pre-clinical candidate milestones. The total amount payable by GSK to Exscientia on achieving these milestones is £33 million.

During this collaboration, Exscientia will work with GSK to discover molecules for disease-related targets.

[Image courtesy: GSK]